Insights into the use of mesenchymal stem cells in COVID-19 mediated acute
respiratory failure
#MMPMID33580031
Durand N
; Mallea J
; Zubair AC
NPJ Regen Med
2020[Oct]; 5
(1
): 17
PMID33580031
show ga
The emergence of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) at
the end of 2019 in Hubei province China, is now the cause of a global pandemic
present in over 150 countries. COVID-19 is a respiratory illness with most
subjects presenting with fever, cough and shortness of breath. In a subset of
patients, COVID-19 progresses to hypoxic respiratory failure and acute
respiratory distress syndrome (ARDS), both of which are mediated by widespread
inflammation and a dysregulated immune response. Mesenchymal stem cells (MSCs),
multipotent stromal cells that mediate immunomodulation and regeneration, could
be of potential benefit to a subset of COVID-19 subjects with acute respiratory
failure. In this review, we discuss key features of the current COVID-19
outbreak, and the rationale for MSC-based therapy in this setting, as well as the
limitations associated with this therapeutic approach.
free
free
free
